A phase II study of talazoparib after platinum or cytotoxic nonplatinum regimens in patients with advanced breast cancer and germline BRCA1/2 mutations (ABRAZO)
Turner, N Telli, M Rugo, H Mailliez, A Ettl, J Grischke, E Mina, L Balmana, J Fasching, P Hurvitz, S
Turner, N
Telli, M
Rugo, H
Mailliez, A
Ettl, J
Grischke, E
Mina, L
Balmana, J
Fasching, P
Hurvitz, S
Citations
Altmetric:
Abstract
PURPOSE:
To assess talazoparib activity in germline BRCA1/2 mutation carriers with advanced breast cancer (aBC).
EXPERIMENTAL DESIGN:
ABRAZO (NCT02034916) was a two-cohort, two-stage, phase II study of talazoparib (1 mg/day) in germline BRCA mutation carriers with a response to prior platinum with no progression on or within 8 weeks of the last platinum dose (cohort 1) or ?3 platinum-free cytotoxic regimens (cohort 2) for aBC. Primary endpoint was confirmed objective response rate (ORR) by independent radiological assessment.
RESULTS:
We enrolled 84 patients (cohort 1, n = 49; cohort 2, n = 35) from May 2014 to February 2016. Median age was 50 (range, 31-75) years. Triple-negative breast cancer incidence was 59% (cohort 1) and 17% (cohort 2). Median number of prior cytotoxic regimens for aBC was two and four, respectively. Confirmed ORR was 21% (95% CI, 10 to 35) (cohort 1) and 37% (95% CI, 22 to 55) (cohort 2). Median duration of response was 5.8 and 3.8 months, respectively. Confirmed ORR was 23% (BRCA1), 33% (BRCA2), 26% (TNBC) and 29% (hormone receptor positive). The most common allgrade adverse events (AEs) included anemia (52%), fatigue (45%), and nausea (42%). Talazoparib-related AEs led to drug discontinuation in three (4%) patients. In an exploratory analysis, longer platinum-free interval was associated with higher response rate in cohort 1 (0% ORR with interval <8 weeks; 47% ORR with interval >6 months).
CONCLUSIONS:
Talazoparib exhibited promising antitumor activity in patients with aBC and germline BRCA mutation.
Description
Date
2018
Publisher
Collections
Keywords
Type
Article
Citation
Turner NC, Telli ML, Rugo HS, Mailliez A, Ettl J, Grischke EM, et al. A phase II study of talazoparib after platinum or cytotoxic nonplatinum regimens in patients with advanced breast cancer and germline BRCA1/2 mutations (ABRAZO). Clin Cancer Res. 2018 Dec 18.